Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects

Basit Öğe Kaydı
dc.authoridSevim, Mustafa/0000-0002-3992-7335
dc.authoridAkbal-Dagistan, Ozlem/0000-0002-6524-3535
dc.authoridYildizPekoz, Ayca/0000-0003-2243-6684
dc.authoridYegen, Berrak/0000-0003-0791-0165
dc.authoridSevim, Mustafa/0000-0002-3992-7335
dc.authoridBasarir, Nur/0000-0002-0695-5292
dc.authoridKaptan, Engin/0000-0003-0866-8796
dc.authorwosidSevim, Mustafa/ABP-1161-2022
dc.authorwosidAkbal-Dagistan, Ozlem/Q-1443-2019
dc.authorwosidYildizPekoz, Ayca/AAD-7826-2020
dc.authorwosidYegen, Berrak/O-6652-2017
dc.authorwosidSANCAR, SERAP/AAC-6532-2020
dc.authorwosidSevim, Mustafa/AAG-4172-2021
dc.authorwosidFael, Hanan/GOG-8124-2022
dc.contributor.authorAkbal-Dagistan, Ozlem
dc.contributor.authorSevim, Mustafa
dc.contributor.authorSen, Leyla Semiha
dc.contributor.authorBasarir, Nur Sena
dc.contributor.authorCulha, Meltem
dc.contributor.authorErturk, Aybige
dc.contributor.authorFael, Hanan
dc.date.accessioned2024-05-19T14:41:27Z
dc.date.available2024-05-19T14:41:27Z
dc.date.issued2022
dc.departmentİstinye Üniversitesien_US
dc.description.abstractFavipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration was associated with systemic side effects in susceptible patients. Considering that the pulmonary route could provide a high drug concentration, and a safer application with less absorption into systemic circulation, it was aimed to elucidate whether favipiravir delivered via soft-mist inhaler has any deleterious effects on lung, liver and kidney tissues of healthy rats. Wistar albino rats of both sexes (n = 72) were placed in restrainers, and were given either saline or favipiravir (1, 2.5, 5 or 10 mg/kg in 1 mL saline) by inhalation within 2 min for 5 consecutive days. On the 6th day, electrocardiographic recording was obtained, and cardiac blood and lung tissues were collected. Favipiravir did not alter cardiac rhythm, blood cell counts, serum levels of alanine transaminase, aspartate transaminase, blood urea nitrogen, creatinine, urea or uric acid, and did not cause any significant changes in the pulmonary malondialdehyde, myeloperoxidase activity or antioxidant glutathione levels. Our data revealed that pulmonary use of favipiravir via soft-mist inhaler enables a high local concentration compared to plasma without oxidative lung injury or cardiac or hepatorenal dysfunction.en_US
dc.identifier.doi10.3390/pharmaceutics14112375
dc.identifier.issn1999-4923
dc.identifier.issue11en_US
dc.identifier.pmid36365193en_US
dc.identifier.urihttps://doi.org10.3390/pharmaceutics14112375
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5112
dc.identifier.volume14en_US
dc.identifier.wosWOS:000883575200001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofPharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectFavipiraviren_US
dc.subjectAntiviralen_US
dc.subjectCovid-19en_US
dc.subjectInhalationen_US
dc.subjectPulmonary Routeen_US
dc.subjectOxidative Lung Injuryen_US
dc.subjectHepatotoxicityen_US
dc.subjectRenal Toxicityen_US
dc.subjectCardiac Toxicityen_US
dc.titlePulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effectsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu